Table 2.

Adverse Events

	Nintedanib n =18	Placebo n=12
Grade 2+ AEs	16	5
Systemic
Fatigue	1 (6%)	1 (8%)
Anorexia	1 (6%)	-
Respiratory
Cough	-	1 (8%)
Dyspnea	3 (17%)	-
Hypoxia	1 (6%)	-
Lung Infection	2 (11%)	-
Pleural effusion	1 (6%)	-
Gastrointestinal
Diarrhea	3 (17%)	-
Nausea	-	1 (8%)
Cardiovascular/Hematologic
Pericardial effusion	1 (6%)	-
Hypertension	1 (6%)	-
Platelet count decreased	1 (6%)	-
Lymphocyte count decreased	-	1 (8%)
Thromboembolic event	1 (6%)	-
Skin
Rash	-	1 (8%)

Grade 2 or higher adverse events that were possibly or probably attributed to the study intervention. Reported as number of patients with at least one occurrence of listed event (percent). No grade 2 events were definitely attributed to intervention. Some patients had multiple adverse events. Two deaths occurred in nintedanib group, unlikely related to study. A full list of all AEs can be found in the supplemental material.